Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal.
EMBO Mol Med. 2024 Apr;16(4):667-669. doi: 10.1038/s44321-024-00056-8. Epub 2024 Mar 21.
Recently licensed subunit vaccines represent the first and, thus far, the only approved agents for vaccination against malaria. However, these vaccines still fail to confer highly effective long-lasting protective immunity. Whole-organism vaccines, employing attenuated sporozoites as immunization agents, constitute a promising alternative for highly effective malaria vaccination. In this issue of , Goswami et al (2024) report on the generation and pre-clinical characterization of genetically attenuated parasites, termed LARC2, whose development arrests at late stages of liver infection. Their results warrant the clinical evaluation of PfSPZ-LARC2 towards its use as a whole-organism vaccine against malaria.
最近获得许可的亚单位疫苗代表了对抗疟疾的第一种疫苗，也是迄今为止唯一获得批准的疫苗。然而，这些疫苗仍然无法提供高效、持久的保护免疫。全病原体疫苗采用减毒的 孢子虫作为免疫制剂，为高效疟疾疫苗接种提供了一种很有前途的替代方法。在本期 杂志中，Goswami 等人（2024 年）报告了一种遗传减毒 的寄生虫的产生和临床前特征，称为 LARC2，其在肝感染的晚期阶段发育停止。他们的研究结果证明，PfSPZ-LARC2 值得在临床上进行评估，作为一种全病原体疟疾疫苗使用。
